2 shot to death in separate attacks on South, West sides









Two men were shot to death in separate attacks within about 15 minutes of each other, one in Austin and one in Back of the Yards, authorities said.


About 9:15 p.m., a man was shot to death inside a Popeyes Louisiana Kitchen, 5500 W. North Ave.


The man, who witnesses said was about 21 years old, was inside a business when he was shot from outside by someone who fled on foot, said Chicago Police News Affairs Officer Amina Greer. He was unresponsive on the scene, she said.








Three workers inside were cleaning up inside as police examined shell casings outside about 10 p.m. Someone fired at least four times from outside the restaurant, piercing a window and striking the man, police said.


An employee who was inside making up an order at the time of the shooting said the gunfire did not sound like shots but instead like someone hitting a table with a hammer.


Just 15 minutes later, a man in his 20s was found shot to death on a sidewalk about 9:30 p.m. in the 5400 block of South Laflin Street, Greer said. He suffered a gunshot wound to the face and was dead on the scene, she said.


Police found him in a gangway next to a house with vacant brick buildings on each side.


Earlier, two men were shot in the Englewood neighborhood tonight. The shooting took place about 7:30 p.m. on the 7300 block of South Racine Avenue, and left one man wounded in the back and the other in the foot, police said.


The Chicago Fire Department said the men were taken to hospitals from nearby locations where they were found by emergency personnel.


A 20-year-old man with a wound to the back was taken from 74th and Racine in serious condition to Advocate Christ Medical Center in Oak Lawn, and an 18-year-old man with a wound to the foot was taken from 74th and Aberdeen Street to St. Bernard Hospital, where his condition was stabilized, according to Fire Media reports.

No further details were immediately available.


lford@tribune.com
Twitter: @ltaford


pnickeas@tribune.com
Twitter: @peternickeas





Read More..

Exclusive: Japan's Sharp cuts iPad screen output


TOKYO/SEOUL (Reuters) - Sharp Corp has nearly halted production of 9.7-inch screens for Apple Inc's iPad, two sources said, possibly as demand shifts to its smaller iPad mini.


Sharp's iPad screen production line at its Kameyama plant in central Japan has fallen to the minimal level to keep the line running this month after a gradual slowdown began at the end of 2012 as Apple manages its inventory, the industry sources with knowledge of Sharp's production plans told Reuters.


Sharp has stopped shipping iPad panels, the people with knowledge of the near total production shutdown said. The exact level of remaining screen output at Sharp was not immediately clear but it was extremely limited, they said.


Company spokeswoman Miyuki Nakayama said: "We don't disclose production levels."


Apple officials, contacted late in the evening after normal business hours in California, did not have an immediate comment.


The sources didn't say exactly why production had nearly halted. Among the possibilities are a seasonal drop in demand, a switch to another supplier, a shift in the balance of sales to the mini iPad, or an update in the design of the product.


Macquarie Research has estimated that iPad shipments will tumble nearly 40 percent in the current quarter to about 8 million from about 13 million in the fourth quarter, although Apple's total tablet shipments will show a much smaller decrease due to strong iPad mini sales.


APPLE SHARES


Any indication that iPad sales are struggling could add to concern that the appeal of Apple products is waning after earlier media reports said it is slashing orders for iPhone 5 screens and other components from its Asian suppliers.


Those reports helped knock Apple's shares temporarily below $500 this week, the first time its stock had been below the threshold mark in almost one year.


Apple, the reports said, has asked state-managed Japan Display, Sharp and LG Display to halve supplies of iPhone panels from an initial plan for about 65 million screens in January-March. Apple is losing ground to Samsung, as well as emerging rivals including China's Huawei Technologies Co Ltd and ZTE Corp.


NO BIG CHANGE AT OTHER MAKERS


In addition to Sharp, Apple also buys iPad screens from LG Display Co Ltd, its biggest supplier, and Samsung Display, a flat-panel unit of Samsung Electronics.


Both LG Display and Samsung Display declined to comment.


A source at Samsung Display, however, said there had not been any significant change in its panel business with Apple, which has been steadily reducing panel purchases from the South Korean firm.


A person who is familiar with the situation at LG Display said iPad screen production in the current quarter had fallen from the previous quarter ending in December, mainly due to weak seasonal demand that is typical after the busy year-end holiday sales period.


Sterne Agee analyst Shaw Wu said some of the product cutbacks at Sharp are probably seasonal.


"The March quarter is almost always weaker than the December quarter," he said, adding that Apple also consolidates suppliers of certain components during quarters with weaker demand. "The Korean manufacturers are more efficient and typically have lower costs."


Apple's iPad sales may have also suffered amid a weak Christmas shopping period that hurt other consumer gadget makers as well.


CROWD OF RIVAL PRODUCTS


Apple also faces stiffening competition in tablets from a growing crowd of rival products from makers including Samsung with its Galaxy and Microsoft Corp's Surface. A consumer shift to smaller 7-inch screen devices, which Apple responded to late last year by launching its iPad mini for $329, are adding pressure.


BNP Paribas expects the iPad mini will eat into sales of the full-sized iPad, with the mini rise to 60 percent of total iPad shipments in the January-March quarter.


Looking to cut into Apple's market share in the smaller segment are Amazon.com Inc with its Kindle and Google Inc with its Nexus 7.


CEO Tim Cook, who is credited with building Apple's Asian supply chain, has overseen several gadget launches, including the iPhone 5, the latest iPad models and the iPad mini during his first year, is under pressure to deliver the kind of product innovations that wowed consumers during Steve Jobs' tenure to keep his company's profit growth stellar.


Sharp, which also supplies screens for the iPhone, has been working with its main banks on a restructuring plan after posting a $5.6 billion loss for the past fiscal year. To secure emergency financing from lenders including Mizuho Financial Group and Mitsubishi Financial Group it had mortgaged its domestic factories and offices including the one building screens for Apple.


In December, Qualcomm Inc agreed to invest as much as $120 million in Sharp and the two companies said they would work to develop new power-saving screens.


(Additional reporting by Poornima Gupta in San Francisco; Writing by Tim Kelly; Editing by Ken Wills and Richard Chang)



Read More..

Armstrong turns emotional in 2nd part of interview


CHICAGO (AP) — Lance Armstrong finally cracked.


Not while expressing deep remorse or regrets, though there was plenty of that in Friday night's second part of Armstrong's interview with Oprah Winfrey.


It wasn't over the $75 million in sponsorship deals that evaporated over the course of two days, or having to walk away from the Livestrong cancer charity he founded and called his "sixth child." It wasn't even about his lifetime ban from competition, though he said that was more than he deserved.


It was another bit of collateral damage that Armstrong said he wasn't prepared to deal with.


"I saw my son defending me and saying, 'That's not true. What you're saying about my dad is not true,'" Armstrong recalled.


"That's when I knew I had to tell him."


Armstrong was near tears at that point, referring to 13-year-old Luke, the oldest of his five children. He blinked, looked away from Winfrey, and with his lip trembling, struggled to compose himself.


It came just past the midpoint of the hourlong program on Winfrey's OWN network. In the first part, broadcast Thursday, the disgraced cycling champion admitted using performance-enhancing drugs when he won seven straight Tour de France titles.


Critics said he hadn't been contrite enough in the first half of the interview, which was taped Monday in Austin, but Armstrong seemed to lose his composure when Winfrey zeroed in on the emotional drama involving his personal life.


"What did you say?" Winfrey asked.


"I said, 'Listen, there's been a lot of questions about your dad. My career. Whether I doped or did not dope. I've always denied that and I've always been ruthless and defiant about that. You guys have seen that. That's probably why you trusted me on it.' Which makes it even sicker," Armstrong said.


"And uh, I told Luke, I said," and here Armstrong paused for a long time to collect himself, "I said, 'Don't defend me anymore. Don't.'


"He said OK. He just said, 'Look, I love you. You're my dad. This won't change that."


Winfrey also drew Armstrong out on his ex-wife, Kristin, whom he claimed knew just enough about both the doping and lying to ask him to stop. He credited her with making him promise that his comeback in 2009 would be drug-free.


"She said to me, 'You can do it under one condition: That you never cross that line again,'" Armstrong recalled.


"The line of drugs?" Winfrey asked.


"Yes. And I said, 'You've got a deal,'" he replied. "And I never would have betrayed that with her."


A U.S. Anti-Doping Agency report that exposed Armstrong as the leader of an elaborate doping scheme on his U.S. Postal Service cycling team included witness statements from at least three former teammates who said Kristin Armstrong participated in or at least knew about doping on the teams and knew team code names for EPO kept in her refrigerator. Postal rider Jonathan Vaughters testified that she handed riders cortisone pills wrapped in foil.


Armstrong said in the first part of the interview that he had stayed clean in the comeback, a claim that runs counter to the USADA report.


And that wasn't the only portion of the interview likely to rile anti-doping officials.


Winfrey asked Armstrong about a "60 Minutes Sports" interview in which USADA chief executive Travis Tygart said a representative of the cyclist had offered a donation that the agency turned down.


"Were you trying to pay off USADA?" she asked.


"No, that's not true," he replied, repeating, "That is not true."


Winfrey asks the question three more times, in different forms.


"That is not true," he insisted.


USADA spokeswoman Annie Skinner replied in a statement: "We stand by the facts both in the reasoned decision and in the '60 Minutes' interview."


Armstrong has talked with USADA officials, and a meeting with Tygart near the Denver airport reportedly ended in an argument over the possibility of modifying the lifetime ban. A person familiar with those conversations said Armstrong could provide information that might get his ban reduced to eight years. By then, he would be 49. The person spoke on condition of anonymity because he was discussing a confidential matter.


After retiring from cycling in 2011, Armstrong returned to triathlons, where he began his professional career as a teenager, and he has told people he's desperate to get back.


Winfrey asked if that was why he agreed to the interview.


"If you're asking me, do I want to compete again ... the answer is hell, yes," Armstrong said. "I'm a competitor. It's what I've done my whole life. I love to train. I love to race. I love to toe the line — and I don't expect it to happen."


Yet just three questions later, a flash of the old Armstrong emerged.


"Frankly," he said, "this may not be the most popular answer, but I think I deserve it. Maybe not right now ... (but) if I could go back to that time and say, 'OK, you're trading my story for a six-month suspension?' Because that's what people got."


"What other people got?" Winfrey asked.


"What everybody got," he replied.


Eleven former Armstrong teammates, including several who previously tested positive for PEDs, testified about the USPS team's doping scheme in exchange for more lenient punishments. Armstrong said in the first part of the interview that he knew his "fate was sealed" when his most trusted lieutenant, George Hincapie, who was alongside him for all seven Tour wins between 1999-2005, was forced to give Armstrong up to anti-doping authorities,


"So I got a death penalty and they got ... six months," Armstrong resumed. "I'm not saying that that's unfair, necessarily, but I'm saying it's different."


Armstrong said the most "humbling" moment in the aftermath of the USADA report was leaving Livestrong lest his association damage the foundation's ability to raise money and continue its advocacy programs on behalf of cancer victims.


Originally called the Lance Armstrong Foundation, the cyclist created it the year after he was diagnosed with a form of testicular cancer that had spread to his brain and lungs. Doctors gave him 50-50 odds of surviving.


"I wouldn't at all say forced out, told to leave," he said of Livestrong. "I was aware of the pressure. But it hurt like hell. ...


"That was the lowest," Armstrong said. "The lowest."


Armstrong's personal fortune had sustained a big hit days earlier. One by one, his sponsors called to end their associations with him: Nike; Trek Bicycles; Giro, which manufactures cycling helmets and other accessories; Anheuser-Busch.


"That was a $75 million day," Armstrong said.


"That just went out of your life," Winfrey said.


"Gone."


"Gone?" Winfrey repeated.


"Gone," he replied, "and probably never coming back."


So was there a moral to his story?


"I can look at what I did," he said. "Cheating to win bike races, lying about it, bullying people. Of course, you're not supposed to do those things. That's what we teach our children."


Armstrong paused to compose himself before a final mea culpa.


"I just think it was about the ride and losing myself, getting caught up in that, and doing all those things along the way that enabled that," he said. "The ultimate crime is, uh, is the betrayal of those people that supported me and believed in me.


"They got lied to."


___


AP Sports Writer Jim Vertuno in Austin, Texas, and National Writer Eddie Pells in Denver contributed to this report.


Read More..

J.J. Abrams to produce Lance Armstrong biopic






LOS ANGELES (AP) — He’s already gotten the Oprah treatment. Now Lance Armstrong is headed for the silver screen.


Paramount Pictures and J.J. Abramsproduction company, Bad Robot, are planning a biopic about the disgraced cyclist, a studio spokeswoman said Friday.






They’ve secured the rights to New York Times reporter Juliet Macur‘s upcoming book “Cycle of Lies: The Fall of Lance Armstrong,” due out in June. Macur covered the seven-time Tour de France winner for over a decade.


No director, writer, star or start date have been set.


Armstrong is in the midst of a two-part interview with Oprah Winfrey in which he admits to using performance-enhancing drugs to reach his historic victories, something he’d defiantly denied for years. The International Olympic Committee stripped him of his 2000 bronze medal this week.


Entertainment News Headlines – Yahoo! News





Title Post: J.J. Abrams to produce Lance Armstrong biopic
Url Post: http://www.news.fluser.com/j-j-abrams-to-produce-lance-armstrong-biopic/
Link To Post : J.J. Abrams to produce Lance Armstrong biopic
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment




Read More..

Lilly drug chosen for Alzheimer's prevention study


Researchers have chosen an experimental drug by Eli Lilly & Co. for a large federally funded study testing whether it's possible to prevent Alzheimer's disease in older people at high risk of developing it.


The drug, called solanezumab (sol-ah-NAYZ-uh-mab), is designed to bind to and help clear the sticky deposits that clog patients' brains.


Earlier studies found it did not help people with moderate to severe Alzheimer's but it showed some promise against milder disease. Researchers think it might work better if given before symptoms start.


"The hope is we can catch people before they decline," which can come 10 years or more after plaques first show up in the brain, said Dr. Reisa Sperling, director of the Alzheimer's center at Brigham and Women's Hospital in Boston.


She will help lead the new study, which will involve 1,000 people ages 70 to 85 whose brain scans show plaque buildup but who do not yet have any symptoms of dementia. They will get monthly infusions of solanezumab or a dummy drug for three years. The main goal will be slowing the rate of cognitive decline. The study will be done at 50 sites in the U.S. and possibly more in Canada, Australia and Europe, Sperling said.


In October, researchers said combined results from two studies of solanezumab suggested it might modestly slow mental decline, especially in patients with mild disease. Taken separately, the studies missed their main goals of significantly slowing the mind-robbing disease or improving activities of daily living.


Those results were not considered good enough to win the drug approval. So in December, Lilly said it would start another large study of it this year to try to confirm the hopeful results seen patients with mild disease. That is separate from the federal study Sperling will head.


About 35 million people worldwide have dementia, and Alzheimer's is the most common type. In the U.S., about 5 million have Alzheimer's. Current medicines such as Aricept and Namenda just temporarily ease symptoms. There is no known cure.


___


Online:


Alzheimer's info: http://www.alzheimers.gov


Alzheimer's Association: http://www.alz.org


___


Follow Marilynn Marchione's coverage at http://twitter.com/MMarchioneAP


Read More..

J.J. Abrams to produce Lance Armstrong biopic


LOS ANGELES (AP) — He's already gotten the Oprah treatment. Now Lance Armstrong is headed for the silver screen.


Paramount Pictures and J.J. Abrams' production company, Bad Robot, are planning a biopic about the disgraced cyclist, a studio spokeswoman said Friday.


They've secured the rights to New York Times reporter Juliet Macur's upcoming book "Cycle of Lies: The Fall of Lance Armstrong," due out in June. Macur covered the seven-time Tour de France winner for over a decade.


No director, writer, star or start date have been set.


Armstrong is in the midst of a two-part interview with Oprah Winfrey in which he admits to using performance-enhancing drugs to reach his historic victories, something he'd defiantly denied for years. The International Olympic Committee stripped him of his 2000 bronze medal this week.


Read More..

Chicago seeks investors for potential Midway Airport deal









Mayor Rahm Emanuel's administration on Friday began testing the investment market's appetite for a potential deal to privatize Midway Airport, launching the process for finding prospective bidders.


The city posted a "request for qualifications," seeking expressions of interest and documentation of credentials from teams interested in financing, operating, maintaining and improving the Southwest Side airport, which is the nation's 26th busiest, with about 9 million passengers passing through annually.


The document reiterates a framework, laid out by Emanuel earlier, aimed at providing city taxpayers with a better deal than the widely criticized 75-year agreement to privatize parking meter operations, carried out during former Mayor Richard Daley's administration. Proceeds from the earlier deal were used to plug operating deficits, and meter rates rose sharply.





This time, proposed leases must be less than 40 years, which locks in the city for a shorter period.


Rather than awarding the city only an upfront payment, the private operator also must share revenue with the city on an ongoing basis. Initial proceeds would be used to pay down debt issued since 1996 to rebuild the airport, the mayor's office said. There is about $1.4 billion in outstanding debt.


Longer term, cash flow would be directed to city infrastructure needs. The mayor has pledged proceeds would not be used to pay for city operations.


The city also is seeking assurances that prices for parking, food and beverages will be kept reasonable.


This is the second time Chicago has looked at privatizing Midway. A 99-year lease that would have brought in $2.5 billion died in 2009 when the financial markets froze up.


Prospective bidders will be asked to prove their ability to raise the needed financing, said Tom Alexander, a spokesman for the mayor.


As in the first go-round, the city is using Credit Suisse Securities LLC as its lead financial adviser.


"The city's process and approach will be thorough and open," Lois Scott, the city's chief financial officer, said in a written statement.


Southwest Airlines, the airport's dominant carrier, supports the move.


Some observers have said a structure with a shorter lease and greater control for the city could translate into lower bids.


But Alexander said the city was confident investors "would gladly meet our terms and still make very attractive offers." The city has declined to estimate how much such a deal could garner.


The request for proposal states "there is significant potential to increase commercial revenue both in terms of variety of activities and increases in sales per passenger."


The city posted the request for qualifications shortly after the Federal Aviation Administration accepted its preliminary application to privatize the airport, clearing the way for the city to move forward in its evaluation process.


Prospective bidders were asked to formally express their interest by Feb. 22. If the city moves forward and seeks proposals, a privatization plan could be submitted to the City Council this summer.


kbergen@tribune.com


Twitter @kathy_bergen





Read More..

Quinn to name former prosecutor Fitzgerald to UI board









Gov. Pat Quinn will name former U.S. Attorney Patrick Fitzgerald to the University of Illinois Board of Trustees, the Tribune has learned.


Fitzgerald will replace first term trustee Lawrence Oliver II, according to a source who was informed of the decision.


The appointment would mark a quick return to the public eye for Fitzgerald, a career prosecutor who left the U.S. attorney's office in Chicago for private law practice in 2012 after a long run that included putting former Govs. George Ryan and Rod Blagojevich behind bars.





Oliver told the Tribune he received a call from Quinn's office Wednesday afternoon with the news that he would not be reappointed. Oliver, who was appointed as a political independent and maintains that affiliation, said he suspects he was not reappointed because he voted in a 2010 Democratic primary.


By law, U. of I. can have no more than five members from any political party, and there are already five Democrats on the board.


Both of the other two board members whose terms expire Monday say they were told they were reappointed to another six-year term. James Montgomery, a Democrat and a Chicago attorney, refused the governor's call to resign during the university scandal over politically connected admissions to the school. Dr. Timothy Koritz, an anesthesiologist at Rockford Memorial Hospital, was appointed by Quinn when he revamped the board in 2009. Koritz, a Republican, was told Wednesday that he would serve a second term.


Quinn’s office is expected to announce the appointments prior to U. of I.'s board meeting next week.


Oliver, chief counsel for investigations at the Boeing Co. who served on Quinn's Illinois Reform Commission, said he was disappointed by the governor's decision. He said he voted in the 2010 Democratic primary to support David Hoffman for U.S. Senate.


U. of I.'s  nine-member board has to be politically balanced, according to state statute. The current board has five Democrats, three Republicans and one Independent.


The U. of I. board is scheduled to meet next Thursday, at which time it will take its annual vote on a chairman and other officers of the board.






Read More..

Intel's weak outlook, spending hikes unnerve Wall Street


SAN FRANCISCO (Reuters) - Intel Corp forecast quarterly revenue that disappointed Wall Street and a sharp increase in capital spending it plans for 2013 unnerved investors already concerned about slow demand for personal computers.


Shares of the world's leading chipmaker slid more than 5 percent in after-hours trade on Thursday after it projected this year's capital spending at $13 billion, plus or minus $500 million, exceeding many analysts' estimates for about $10 billion.


Intel said $2 billion of its increased expenditures would go toward expanding a facility for researching future manufacturing technology. Some analysts worried that with PC sales already slow, expanding too quickly may create excess capacity that could hurt the bottom line.


"People are starting to freak out about the capex," said Sanford C. Bernstein analyst Stacy Rasgon. "The concern is that if I spend a lot of money and I build up my factories, I don't have enough demand to fill them. They have very high fixed costs, and it pulls your margins down."


Outgoing Chief Executive Paul Otellini, who plans to retire in May after a successor is identified, said the investment in manufacturing would lower costs in the long run.


"The leading edge capacity is the lowest cost for us on a per unit basis," Otellini told analysts on a conference call. "Regardless of what you think the size of the market is, the leading edge fabs are the single greatest asset that we have."


Otellini said the higher capex is not intended to bankroll a foundry or contract chipmaking business, but he did not rule out manufacturing semiconductors for other chip companies as long as that did not empower a rival.


Intel has agreed to manufacture custom chips on behalf of networking equipment company Cisco Systems Inc, Bloomberg reported on Thursday. An Intel spokesman declined to comment.


In the fourth quarter, Intel's revenue was $13.5 billion, compared with $13.9 billion a year earlier. Analysts had expected $13.53 billion.


It estimated first-quarter revenue of $12.7 billion, plus or minus $500 million. Analysts expected $12.91 billion.


STRUGGLING IN MOBILE


Intel is used to being king of the personal computer market, particularly through its historic Wintel alliance with Microsoft Corp, which has led to breathtakingly high profit margins and an 80 percent market share.


But it has struggled to adapt its technology for smartphones and tablets, a market dominated by Qualcomm Inc, Samsung Electronics Co Ltd and Nvidia Corp. PC makers are struggling to stop a decline in sales as consumers hold off on buying new laptops in favor of more nimble mobile gadgets.


Microsoft's long-awaited launch of Windows 8 in October brought touchscreen features to laptops but failed to spark a resurgence in sales that Intel and many PC manufacturers had hoped for.


Intel's hefty investment plans reflect its confidence in the future, even as Wall Street worries about the chipmaker's struggle to gain traction in the mobile market.


"Our core advantage really is our manufacturing leadership," Chief Financial Officer Stacy Smith told Reuters. "450 will give us a significant cost advantage relative to others."


Intel is expanding its research fab in Hillsboro, Oregon, to develop technology for manufacturing chips on 450 mm silicon wafers, a complicated step up from the current 300 mm wafer standard.


Larger wafers can translate into big savings because more chips can be etched onto each of them. But building 450 mm plants is expected to be so expensive that only a few industry leaders, including Intel, Samsung Electronics and TSMC, are expected to have the necessary scale.


Some Wall Street analysts gave Intel high marks for expected operating efficiency this year.


"The revenue isn't going to be there, but the margin and expense control is going to stabilize the bottom line," said Cody Acree, an analyst at Williams Financial. "I think it's probably a success if you can be flat in an industry that most people expect to be flat to down."


Intel foresees first-quarter gross margins of 58 percent, plus or minus two percentage points. Analysts on average expected gross margins of about 56 percent for the current quarter, according to Thomson Reuters I/B/E/S.


It estimated a 2013 gross margin of 60 percent, plus or minus a few percentage points. Analysts on average had expected 59 percent.


Net earnings in the December quarter were $2.5 billion, or 48 cents a share, compared with $3.4 billion, or 64 cents a share, year-ago period.


Analysts had expected 45 cents, and said the surprisingly strong performance was partly due to a lower effective tax rate of 23 percent. This was below Intel's forecast of about 27 percent.


Still, shares of Intel fell 5.6 percent in after-hours trade to $21.43, after closing up 2.58 percent at $22.68 on the Nasdaq.


"This is a company that is continuing to spend money to participate in the market. That may concern some investors," said Doug Freedman, an analyst at RBC Capital.


(Reporting by Noel Randewich; Editing by Richard Chang and Steve Orlofsky)



Read More..

Armstrong admits doping: 'I'm a flawed character'


CHICAGO (AP) — He did it. He finally admitted it. Lance Armstrong doped.


He was light on the details and didn't name names. He mused that he might not have been caught if not for his comeback in 2009. And he was certain his "fate was sealed" when longtime friend, training partner and trusted lieutenant George Hincapie, who was along for the ride on all seven of Armstrong's Tour de France wins from 1999-2005, was forced to give him up to anti-doping authorities.


But right from the start and more than two dozen times during the first of a two-part interview Thursday night with Oprah Winfrey on her OWN network, the disgraced former cycling champion acknowledged what he had lied about repeatedly for years, and what had been one of the worst-kept secrets for the better part of a week: He was the ringleader of an elaborate doping scheme on a U.S. Postal Service team that swept him to the top of the podium at the Tour de France time after time.


"I'm a flawed character," he said.


Did it feel wrong?


"No," Armstrong replied. "Scary."


"Did you feel bad about it?" Winfrey pressed him.


"No," he said. "Even scarier."


"Did you feel in any way that you were cheating?"


"No," Armstrong paused. "Scariest."


"I went and looked up the definition of cheat," he added a moment later. "And the definition is to gain an advantage on a rival or foe. I didn't view it that way. I viewed it as a level playing field."


Wearing a blue blazer and open-neck shirt, Armstrong was direct and matter-of-fact, neither pained nor defensive. He looked straight ahead. There were no tears and very few laughs.


He dodged few questions and refused to implicate anyone else, even as he said it was humanly impossible to win seven straight Tours without doping.


"I'm not comfortable talking about other people," Armstrong said. "I don't want to accuse anybody."


Whether his televised confession will help or hurt Armstrong's bruised reputation and his already-tenuous defense in at least two pending lawsuits, and possibly a third, remains to be seen. Either way, a story that seemed too good to be true — cancer survivor returns to win one of sport's most grueling events seven times in a row — was revealed to be just that.


"This story was so perfect for so long. It's this myth, this perfect story, and it wasn't true," he said.


Winfrey got right to the point when the interview began, asking for yes-or-no answers to five questions.


Did Armstrong take banned substances? "Yes."


Did that include the blood-booster EPO? "Yes."


Did he do blood doping and use transfusions? "Yes."


Did he use testosterone, cortisone and human growth hormone? "Yes."


Did he take banned substances or blood dope in all his Tour wins? "Yes."


In his climb to the top, Armstrong cast aside teammates who questioned his tactics, yet swore he raced clean and tried to silence anyone who said otherwise. Ruthless and rich enough to settle any score, no place seemed beyond his reach — courtrooms, the court of public opinion, even along the roads of his sport's most prestigious race.


That relentless pursuit was one of the things that Armstrong said he regretted most.


"I deserve this," he said twice.


"It's a major flaw, and it's a guy who expected to get whatever he wanted and to control every outcome. And it's inexcusable. And when I say there are people who will hear this and never forgive me, I understand that. I do. ...


"That defiance, that attitude, that arrogance, you cannot deny it."


Armstrong said he started doping in mid-1990s but didn't when he finished third in his comeback attempt.


Anti-doping officials have said nothing short of a confession under oath — "not talking to a talk-show host," is how World Anti-Doping Agency director general David Howman put it — could prompt a reconsideration of Armstrong's lifetime ban from sanctioned events.


He's also had discussions with officials at the U.S. Anti-Doping Agency, whose 1,000-page report in October included testimony from nearly a dozen former teammates and led to stripping Armstrong of his Tour titles. Shortly after, he lost nearly all his endorsements, was forced to walk away from the Livestrong cancer charity he founded in 1997, and just this week was stripped of his bronze medal from the 2000 Olympics.


Armstrong could provide information that might get his ban reduced to eight years. By then, he would be 49. He returned to triathlons, where he began his professional career as a teenager, after retiring from cycling in 2011, and has told people he's desperate to get back.


Initial reaction from anti-doping officials ranged from hostile to cool.


WADA president John Fahey derided Armstrong's defense that he doped to create "a level playing field" as "a convenient way of justifying what he did — a fraud."


"He was wrong, he cheated and there was no excuse for what he did," Fahey said by telephone in Australia.


If Armstrong "was looking for redemption," Fahey added, "he didn't succeed in getting that."


USADA chief Travis Tygart, who pursued the case against Armstrong when others had stopped, said the cyclist's confession was just a start.


"Tonight, Lance Armstrong finally acknowledged that his cycling career was built on a powerful combination of doping and deceit," Tygart said. "His admission that he doped throughout his career is a small step in the right direction. But if he is sincere in his desire to correct his past mistakes, he will testify under oath about the full extent of his doping activities."


Livestrong issued a statement that said the charity was "disappointed by the news that Lance Armstrong misled people during and after his cycling career, including us."


"Earlier this week, Lance apologized to our staff and we accepted his apology in order to move on and chart a strong, independent course," it said.


The interview revealed very few details about Armstrong's performance-enhancing regimen that would surprise anti-doping officials.


What he called "my cocktail" contained the steroid testosterone and the blood-booster erythropoetein, or EPO, "but not a lot," Armstrong said. That was on top of blood-doping, which involved removing his own blood and weeks later re-injecting it into his system.


All of it was designed to build strength and endurance, but it became so routine that Armstrong described it as "like saying we have to have air in our tires or water in our bottles."


"That was, in my view, part of the job," he said.


Armstrong was evasive, or begged off entirely, when Winfrey tried to connect his use to others who aided or abetted the performance-enhancing scheme on the USPS team


When she asked him about Italian doctor Michele Ferrari, who was implicated in doping-related scrapes and has also been banned from cycling for life, Armstrong replied, "It's hard to talk about some of these things and not mention names. There are people in this story, they're good people and we've all made mistakes ... they're not monsters, not toxic and not evil, and I viewed Michele Ferrari as a good man and smart man and still do."


But that's nearly all Armstrong would say about the physician that some reports have suggested educated the cyclist about doping and looked after other aspects of his training program.


He was almost as reluctant to discuss claims by former teammates Tyler Hamilton and Floyd Landis that Armstrong told them, separately, that he tested positive during the 2001 Tour de Suisse and conspired with officials of the International Cycling Union officials to cover it up — in exchange for a donation.


"That story wasn't true. There was no positive test, no paying off of the labs. There was no secret meeting with the lab director," he said.


Winfrey pressed him again, asking if the money he donated wasn't part of a tit-for-tat agreement, "Why make it?"


"Because they asked me to," Armstrong began.


"This is impossible for me to answer and have anybody believe it," he said. "It was not in exchange for any cover-up. ... I have every incentive here to tell you yes."


Finally, he summed up the entire episode this way: "I was retired. ... They needed money."


Ultimately, though, it was Landis who did the most damage to Armstrong's story. Landis was stripped of the 2006 Tour title after testing positive and wound up on the sport's fringes looking for work. Armstrong said his former teammate threatened to release potentially destructive videos if he wasn't given a spot on the team. That was in 2009, when Armstrong returned to the Tour after four years off.


Winfrey asked whether Landis' decision to talk was "the tipping point."


"I'd agree with that. I might back it up a little and talk about the comeback. I think the comeback didn't sit well with Floyd," Armstrong recalled.


"Do you regret now coming back?"


"I do. We wouldn't be sitting here if I didn't come back," he said.


The closest Armstrong came to contrition was when Winfrey asked him about his apologies in recent days, notably to former teammate Frankie Andreu, who struggled to find work in cycling after Armstrong dropped him from the USPS team, as well as his wife, Betsy. Armstrong said she was jealous of his success, and invented stories about his doping as part of a long-running vendetta.


"Have you made peace?" Winfrey asked.


"No," Armstrong replied, "because they've been hurt too badly, and a 40-minute (phone) conversation isn't enough."


He also called London Sunday Times reporter David Walsh as well as Emma O'Reilly, who worked as a masseuse for the USPS team and later provided considerable material for a critical book Walsh wrote about Armstrong and his role in cycling's doping culture.


Armstrong subsequently sued for libel in Britain and won a $500,000 judgment against the newspaper, which is now suing to get the money back. Armstrong was, if anything, even more vicious in the way he went after O'Reilly. He intimated she was let go from the Postal team because she seemed more interested in personal relationships than professional ones.


"What do you want to say about Emma O'Reilly?" Winfrey asked.


"She, she's one of these people that I have to apologize to. She's one of these people that got run over, got bullied."


"You sued her?"


"To be honest, Oprah, we sued so many people I don't even," Armstrong said, then paused, "I'm sure we did."


Near the end of the first interview installment, Winfrey asked about a federal investigation of Armstrong that was dropped by the Justice Department without charges.


"When they dropped the case, did you think: 'Now, finally over, done, victory'?"


Armstrong looked up. He exhaled.


"It's hard to define victory," he said. "But I thought I was out of the woods."


___


AP Sports Writers Jim Vertuno in Austin, Texas, Eddie Pells in Denver and Dennis Passa in Melbourne contributed to this report.


Read More..